Home LiteratureArticle Details
PMID: 24095974 Published · ppublish English Evaluation Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis.

Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P, Singal AG

Abstract

Measurements of α-fetoprotein (AFP) detect hepatocellular carcinoma (HCC) with low levels of sensitivity and specificity, and therefore are not recommended for use in liver cancer surveillance. However, AFP levels might accurately detect HCC in subgroups of patients. We performed a retrospective case-control study to identify features of patients with cirrhosis in whom levels of AFP correlated with HCC. We collected data from patients with cirrhosis, with (n = 452) or without (n = 676) HCC, diagnosed at Parkland Hospital in Dallas, Texas, from January 2005 through June 2012. We determined sensitivities and specificities with which different levels of AFP identified those with HCC; multivariate logistic regression was used to associate accurate identification of HCC with patient features (age, sex, race/ethnicity, alcohol intake, smoking, etiology of cirrhosis, presence of decompensation, and laboratory test results). We assessed the overall accuracy of these factors in detecting HCC using receiver operator characteristic curve analysis and the Delong method. We calculated levels of AFP that detect HCC with the highest levels of sensitivity and specificity in subgroups using receiver operator characteristic analysis. The most common etiologies of cirrhosis were hepatitis C virus (HCV) infection (60%) and alcohol induced (22%). Nearly 11% of patients were human immunodeficiency virus (HIV)-positive. Levels of AFP greater than 20 ng/mL detected HCC with 70.1% sensitivity and 89.8% specificity. This AFP level identified patients with HCC with a c-statistic of 0.87 (95% confidence interval, 0.85-0.89); it was significantly more accurate in HCV-negative patients than in HCV-positive patients (c-statistic, 0.89 vs 0.83; P = .007). AFP levels of 59 ng/mL or greater most accurately detected HCC in patients with HCV-associated cirrhosis; levels of AFP of 11 ng/mL or greater accurately identified HCC in HCV-negative patients. The level of AFP identified early stage HCC with a c-statistic of 0.62 (95% confidence interval, 0.58-0.66), and had a significantly higher level of accuracy for HIV-positive patients than for HIV-negative patients (c-statistic, 0.81 vs 0.59; P < .001). Based on a retrospective analysis of data from patients with cirrhosis, with or without HCC, AFP level most accurately detects HCC in patients without HCV infection. It detects HCC with a high level of accuracy in patients with cirrhosis and HIV infection.

Keywords
AIDS Biomarkers Liver Disease Screening
MeSH Terms
Biomarkers/blood Carcinoma, Hepatocellular/diagnosis Case-Control Studies Female Humans Liver Cirrhosis/complications Liver Neoplasms/diagnosis Male Middle Aged Retrospective Studies Sensitivity and Specificity Texas alpha-Fetoproteins/analysis
Chemicals
Biomarkers alpha-Fetoproteins
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Gopal Purva
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
Yopp Adam C
Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas; Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Waljee Akbar K
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan; Center for Clinical Management Research, Ann Arbor Veterans Affairs Healthcare Systems, Ann Arbor, Michigan.
Chiang Jason
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Nehra Mahendra
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Kandunoori Pragathi
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Singal Amit G
Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: [email protected].
References (26)
26 references, click to expand
  1. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis.
    Ann Intern Med. 2003 Jul 1;139(1):46-50 PMID: 12834318
  2. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status.
    Am J Gastroenterol. 2003 Sep;98(9):2060-3 PMID: 14499788
  3. ROC curves, test accuracy, and the description of diagnostic tests.
    J Neuropsychiatry Clin Neurosci. 1991 Summer;3(3):330-3 PMID: 1821250
  4. Improving screening for hepatocellular carcinoma by incorporating data on levels of α-fetoprotein, over time.
    Clin Gastroenterol Hepatol. 2013 Apr;11(4):437-40 PMID: 23247324
  5. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?
    Am J Gastroenterol. 2013 Mar;108(3):425-32 PMID: 23337478
  6. Failure rates in the hepatocellular carcinoma surveillance process.
    Cancer Prev Res (Phila). 2012 Sep;5(9):1124-30 PMID: 22846843
  7. Epidemiology of hepatocellular carcinoma in Hispanics in the United States.
    Arch Intern Med. 2007 Oct 8;167(18):1983-9 PMID: 17923599
  8. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.
    Hepatogastroenterology. 2000 Nov-Dec;47(36):1654-8 PMID: 11149026
  9. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.
    Cancer Biomark. 2007;3(2):79-87 PMID: 17522429
  10. Use of administrative claims data for identifying patients with cirrhosis.
    J Clin Gastroenterol. 2013 May-Jun;47(5):e50-4 PMID: 23090041
  11. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma.
    Am J Gastroenterol. 2013 Nov;108(11):1723-30 PMID: 24169273
  12. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.
    Hepatology. 2010 May;51(5):1820-32 PMID: 20432259
  13. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.
    Am J Gastroenterol. 2012 Jan;107(1):64-74 PMID: 21931376
  14. Whither (wither?) the ultrasound specialist?
    J Ultrasound Med. 2004 Dec;23(12):1543-7 PMID: 15557297
  15. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.
    J Hepatol. 2001 Apr;34(4):570-5 PMID: 11394657
  16. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis.
    Hepatology. 2002 Aug;36(2):410-7 PMID: 12143050
  17. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.
    J Hepatol. 2007 Oct;47(4):527-37 PMID: 17692986
  18. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis.
    Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):793-9 PMID: 22374994
  19. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma.
    Clin Gastroenterol Hepatol. 2011 Jan;9(1):64-70 PMID: 20831903
  20. Epidemiology of viral hepatitis and hepatocellular carcinoma.
    Gastroenterology. 2012 May;142(6):1264-1273.e1 PMID: 22537432
  21. Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection.
    Clin Gastroenterol Hepatol. 2012 Nov;10(11):1284-90 PMID: 22902759
  22. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.
    Aliment Pharmacol Ther. 2009 Jul;30(1):37-47 PMID: 19392863
  23. Is AFP a new reliable marker of liver regeneration in acute hepatic failure?
    J Gastroenterol. 2002;37(8):681-2 PMID: 12203090
  24. Epidemiology of non-alcoholic fatty liver disease.
    Dig Dis. 2010;28(1):155-61 PMID: 20460905
  25. Use of the AST to platelet ratio index in HCV/HIV co-infected patients.
    Aliment Pharmacol Ther. 2011 Mar;33(5):566-77 PMID: 21205257
  26. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.
    J Hepatol. 2005 Sep;43(3):434-41 PMID: 16136646
Article Info
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Abbr.
Clin Gastroenterol Hepatol
ISSN
1542-7714
Published
2014-05-00
Epub
2013-00-02
Pages
870-7
Language
English
Region
United States
NLM ID
101160775
PMCID
PMC3975698
Subset
IM
Grants
NCATS NIH HHS · UL1 TR001105 · United States
NCATS NIH HHS · UL1 TR000451 · United States
HSRD VA · IK2 HX000775 · United States
NCATS NIH HHS · KL2 TR001103 · United States
NCATS NIH HHS · KL2 TR000453 · United States
NCATS NIH HHS · UL1-TR000451 · United States
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]